|
1) Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006, 17: 1181-91
|
|
|
|
2) Port FK, Pisoni RL, Bommer J, et al. Improving outcomes for dialysis patients in the international Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol. 2006; 1: 246-55
|
|
|
|
|
|
3) Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-84
|
|
|
|
|
|
4) Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-90
|
|
|
|
|
|
5) Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-98
|
|
|
|
|
|
6) 日本透析医学会. 2004年版日本透析医学会｢慢性血液透析患者における腎性貧血治療のガイドライン｣. 透析会誌. 2004; 37: 1737-63
|
|
|
|
|
|
7) 平澤由平, 鈴木正司. 他血液透析患者に対する遺伝子組換えヒトエリスロポエチン製剤(rHuEPO)治療における維持Ht値と生命予後に関する大規模調査(rHuEPO特別調査). 透析会誌. 2003; 36: 1265-72
|
|
|
|
|
|
8) Akizawa T, Pisoni RL, Akiba T, et al. Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS. Nephrol Dial Transplant. 2008; 23: 3643-53
|
|
|
|
|